Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity. Germline BRCA2 mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy. Isn't Androgen Deprivation Enough? Optimal Treatment for Newly Diagnosed Metastatic Prostate Cancer. Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. 2022 07 257(3):274-284.ĭetecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. 2022 06 16(12):2384-2395.Ĭomparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies. The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. 2022 07 82(1):115-141.Ĭorrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021". Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. 2022 May 20 Suppl 9(5):1-20.Įditorial: Metastatic prostate cancer: a wealth of data to put into practice. 2022 05 20 Suppl 9(5):2-8.įactors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Recent clinical trial data of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. ![]() 2022 05 27 376(6596):eabe1505.Īllele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. 2022 07 01 28(13):2771-2778.Ĭhromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNa ± Bevacizumab: Results from CALGB 90206 (Alliance). 2023 01 9(1):110-113.įuture directions for precision oncology in prostate cancer. Moving Precision Oncology for Advanced Prostate Cancer from Theory to Practice. 2022 11 01 132(21).ĬHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2. 2022 11 6:e2200382.Ī clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer. Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer. 2022 11 07 12(1):18879.ĭL元 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. The NOGO receptor NgR2, a novel aVß3 integrin effector, induces neuroendocrine differentiation in prostate cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Management of Patients with Advanced Prostate Cancer. Impact of early detection on cancer curability: A modified Delphi panel study. ![]() In addition, within Dana Farber and through national and international collaborations, we work with a multidisciplinary team of scientists and clinicians towards the development of next generation molecular platforms and biomarkers for the clinical application of precision medicine across tumor types. Our mission is to make discoveries that improve the way we manage and treat patients with advanced prostate cancer. We are developing tissue and circulating biomarkers and novel therapeutic strategies for clinical translation. We have used genomics and epigenomics to elucidate the molecular mechanisms driving evolution towards an AR-low state. We have focused on understanding mechanisms underlying an emerging subclass of androgen-indifferent prostate cancers that develop neuroendocrine features as an adaptive response mechanism upon selective therapeutic pressure of the androgen receptor (AR). My lab is focused on understanding mechanisms of treatment resistance in advanced prostate cancer through the integration of clinical and molecular features of patients combined with preclinical modeling. The Beltran lab is focused on understanding mechanisms of treatment resistance in prostate cancer including lineage plasticity and the development of neuroendocrine prostate cancer
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |